| 3.11 -0.1 (-3.12%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.95 |
1-year : | 5.82 |
| Resists | First : | 4.24 |
Second : | 4.98 |
| Pivot price | 3.58 |
|||
| Supports | First : | 3.02 |
Second : | 2.52 |
| MAs | MA(5) : | 3.26 |
MA(20) : | 3.87 |
| MA(100) : | 5.13 |
MA(250) : | 4.63 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 6.1 |
D(3) : | 9.6 |
| RSI | RSI(14): 31.6 |
|||
| 52-week | High : | 7.17 | Low : | 2.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MYO ] has closed above bottom band by 30.4%. Bollinger Bands are 72.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.16 - 3.19 | 3.19 - 3.21 |
| Low: | 2.97 - 3.01 | 3.01 - 3.03 |
| Close: | 3.06 - 3.13 | 3.13 - 3.17 |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Mon, 19 May 2025
Balyasny Asset Management L.P. Takes $108,000 Position in Myomo, Inc. (NYSEAMERICAN:MYO) - Defense World
Thu, 15 May 2025
Insider Buying: Thomas Kirk Acquires Shares of Myomo Inc (MYO) - GuruFocus
Wed, 14 May 2025
Insider Buying: Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO) - GuruFocus
Thu, 08 May 2025
Myomo Inc Reports Strong Q1 Revenue Amid Challenges - TipRanks
Thu, 08 May 2025
Myomo Inc (MYO) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic Innovations - Yahoo Finance
Wed, 07 May 2025
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 30 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 13 (%) |
| Held by Institutions | 47.6 (%) |
| Shares Short | 938 (K) |
| Shares Short P.Month | 714 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | -44.8 % |
| Operating Margin | -14.9 % |
| Return on Assets (ttm) | -40.2 % |
| Return on Equity (ttm) | -102.2 % |
| Qtrly Rev. Growth | 26.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.69 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -11.52 |
| PEG Ratio | 45.9 |
| Price to Book value | 9.71 |
| Price to Sales | 4.45 |
| Price to Cash Flow | -10.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|